variables | Groups | Positive BCL2 | Negative BCL2 | total | Chi-square test P-value |
Tumor site | Nodal | 22 (78.6%) | 6 (21.4%) | 28 | 0.758 |
Extranodal | 14 (82.4%) | 3 (17.6%) | 17 | ||
Ann Arbor stage | I & II | 26 (78.8%) | 7 (21.2%) | 33 | 0.736 |
III & IV | 10 (83.3%) | 2 (16.7%) | 12 | ||
Age group | <60 years | 27 (77.1%) | 8 (22.9%) | 35 | 0.37 |
≥60 years | 9 (90%) | 1 (10%) | 10 | ||
recurrence | Present | 17 (94.4%) | 1 (5.6%) | 18 | 0.048 |
Free | 19 (70.4%) | 8 (29.6%) | 27 | ||
Died/alive status | Died | 9 (100%) | Zero | 9 | 0.094 |
Alive | 27 (75%) | 9 (25%) | 36 | ||
Patient Response to chemotherapy | Respond to < 3 courses | 8 (57.1%) | 6 (42.9%) | 14 | 0.033 |
Respond to ≥ 3 courses | 14 (87.5%) | 2 (12.5%) | 16 | ||
Resistant | 14 (93.3%) | 1 (6.7%) | 15 |